PW Medtech sees revenue jump 22.4% on blood purification, profit slips

For the six months ended June 30, 2025, PW Medtech Group's total revenue increased by 22.4% to RMB414.4 million, up from RMB338.4 million in the same period of 2024. This growth was primarily fueled by the Blood Purification Business, which saw a 44.5% revenue increase to RMB297.4 million. Gross profit for the period rose by 13.4% to RMB212.8 million, though the gross profit margin decreased from 55.4% to 51.3%, mainly due to lower unit sales prices in the Blood Purification Business.

Profit attributable to owners of the company, however, decreased by 6.0% to RMB66.0 million from RMB70.2 million in the prior year, influenced by lower operating profit and finance income. Adjusted net profit attributable to owners, a non-HKFRS measure, increased by 10.9% to RMB83.4 million. The board declared an interim dividend of HK4.4 cents per share for the six months ended June 30, 2025.

The company's Infusion Set Business experienced a 14.5% revenue decrease to RMB113.4 million, attributed to expanded volume-based procurement policies and softer market demand. Conversely, the Regenerative Medical Biomaterials Business made its revenue debut, contributing RMB3.5 million, primarily from the successful launch of a breast tissue patch.